Celldex Therapeutics, Inc.
CLDX
$27.81
$1.144.27%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 5.04% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 5.04% | |||
| Cost of Revenue | 16.12% | 3.01% | |||
| Gross Profit | -17.70% | -2.98% | |||
| SG&A Expenses | 2.84% | -3.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.98% | 1.82% | |||
| Operating Income | -15.28% | -1.78% | |||
| Income Before Tax | -18.45% | -5.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -18.45% | -5.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -18.45% | -5.21% | |||
| EBIT | -15.28% | -1.78% | |||
| EBITDA | -15.57% | -1.80% | |||
| EPS Basic | -18.40% | -5.19% | |||
| Normalized Basic EPS | -18.41% | -5.19% | |||
| EPS Diluted | -18.40% | -5.19% | |||
| Normalized Diluted EPS | -18.41% | -5.19% | |||
| Average Basic Shares Outstanding | 0.04% | 0.01% | |||
| Average Diluted Shares Outstanding | 0.04% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||